API Nateglinide

Nateglinide More Info

Product Overview

Nateglinide is a meglitinide-class antidiabetic medication used as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus. The brand name product was Starlix, which was developed by Novartis. Available strengths include 60 mg and 120 mg oral tablets.

Therapeutic Indications

Nateglinide is indicated as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus. It is not approved for type 1 diabetes mellitus or diabetic ketoacidosis. Pediatric use has not been established for patients under 18 years of age.

Mechanism of Action

Nateglinide stimulates insulin release from pancreatic beta cells in a glucose-dependent manner. Unlike sulfonylureas, it has minimal effect on insulin release when glucose levels are low. The drug potentiates the effect of extracellular glucose on ATP-sensitive potassium channels and binds less avidly to SUR1 receptors compared to sulfonylureas, resulting in a shorter duration of action. This selectivity primarily lowers postprandial glucose levels with minimal effect on fasting plasma glucose.

Pharmacokinetic Properties

Nateglinide is rapidly and completely absorbed with a bioavailability of approximately 73%. Peak plasma concentrations occur 45-60 minutes after ingestion. The drug is highly protein-bound at approximately 98% and is extensively metabolized in the liver primarily by CYP2C9, with CYP3A4 playing a minor role. Active metabolites account for the majority of systemic exposure and possess one-third to one-sixth of the potency of the parent compound. The elimination half-life is approximately 1.5 hours. Approximately 97% of the drug is excreted renally. Food intake significantly delays absorption, emphasizing the importance of proper timing relative to meals.

Dosage and Administration

The standard starting dose is 120 mg administered three times daily before meals. If the patient is near their glycemic treatment goal, a 60 mg dose may be appropriate. The maximum recommended dose is 180 mg three times daily, totaling 540 mg per day. Patients should take nateglinide one to thirty minutes before each main meal. If a meal is skipped, the dose should also be skipped to reduce the risk of hypoglycemia. Dose reduction may be necessary in patients with severe renal impairment. The product should be stored at controlled room temperature and protected from light and moisture.

Adverse Reactions

Common adverse reactions include hypoglycemia, which is the most significant safety concern. Gastrointestinal side effects such as diarrhea, nausea, and dyspepsia are frequently reported. Neurological effects include dizziness and headache. Upper respiratory tract infections, back pain, arthropathy, flu-like symptoms, and weight gain have also been observed. Severe adverse reactions requiring immediate medical attention include signs of allergic reaction such as hives, difficulty breathing, or swelling of the face, lips, tongue, or throat. Seizures and severe hypoglycemia with symptoms including cold sweats, confusion, extreme tiredness, and vision changes also warrant urgent medical evaluation.

Drug Interactions

Concurrent use of gemfibrozil, fluconazole, ACE inhibitors, sulfonylureas, other hypoglycemic agents, and alcohol may enhance the hypoglycemic effect of nateglinide. Rifampicin, diuretics, corticosteroids, beta-blockers, and phenytoin may reduce the hypoglycemic efficacy of the drug. Patients should inform their healthcare providers of all concomitant medications.

Contraindications and Special Populations

Nateglinide is contraindicated in patients with known hypersensitivity to the drug or any of its inactive ingredients, in those with type 1 diabetes mellitus, and in patients with diabetic ketoacidosis. During pregnancy, the drug should be used only if clearly needed and after consulting a physician. Breastfeeding is contraindicated during nateglinide treatment as the drug passes into breast milk. The medication is not approved for use in children under 18 years of age. Elderly patients should use this medication with caution and be monitored closely. Patients with renal impairment may require dose adjustment based on their renal function.

Clinical Efficacy

Clinical trials involved approximately 2,600 patients with type 2 diabetes mellitus who received nateglinide treatment. Of these, 1,335 patients were treated for six months or longer, and 190 patients were treated for one year or longer. The studies demonstrated efficacy in reducing postprandial blood glucose levels. Nateglinide showed comparable efficacy to sulfonylureas in reducing HbA1c levels.

Patient Counseling Points

Patients should be educated on recognizing and managing hypoglycemia. Maintaining a healthy diet and regular exercise is essential for optimal glycemic control. Medication should be taken consistently with meals, and the dose should be skipped if a meal is skipped. Regular blood glucose monitoring is essential for therapy management. Patients should consider carrying medical identification that indicates their diabetes treatment status.

Storage Instructions

Store at controlled room temperature between 20-25°C. Keep the medication in its original container and protect it from moisture and light to maintain stability and efficacy.

Product Availability

Novartis discontinued nateglinide production in 2020. Generic formulations may still be accessible from alternative manufacturers depending on the region. Repaglinide (Prandin) is a pharmacologically similar alternative within the meglitinide class that patients may discuss with their healthcare provider as a substitute.

Summary

Nateglinide is a rapid-acting insulin secretagogue belonging to the meglitinide class of medications. It is indicated for type 2 diabetes mellitus as an adjunct to diet and exercise. The typical dosing is 60-120 mg three times daily before main meals. The drug achieves peak effect 45-60 minutes after administration and has a short duration of action with minimal effects on fasting glucose levels. Key advantages include flexible dosing and a lower risk of hypoglycemia compared to sulfonylureas. The major safety concern is hypoglycemia, particularly in patients with renal impairment.